Abstract
Historically, the human basophil that is studied experimentally comes from peripheral blood. But there is evidence that only a short portion of the basophil life cycle related to IgE-mediated function occurs in the blood. The same evidence suggests that IgE-mediated functionality is present for 5–7 days in the bone marrow (or other tissues) during which the cell modulates its phenotype according to local conditions. It is suggested that to properly understand the nature of basophil behavior, a better understanding of its biology during maturation would be helpful. For example, one highly suggestive line of evidence for the relevance of understanding the maturation period is related to the change in basophil phenotype that occurs during treatment of patients with omalizumab. During this treatment, the intrinsic reactivity or sensitivity of the basophils is significantly increased despite, or perhaps because of, the dramatic reduction in FcεRI expression that accompanies this treatment. One of the critical signaling enzymes to increase expression selectively in basophils during treatment is SYK, which is one of the earliest signaling tyrosine kinases involved in translating the aggregation of FcεRI into secretion from the cell. Treatment with omalizumab increases SYK expression, and this observation focuses some attention of how SYK expression is regulated. It is possible that the key regulation occurs during maturation of the basophil. Regardless of the mechanisms operative in this particular treatment, understanding the process of maturation and the extrinsic factors that influence it may lead to better understanding of disease processes. Therefore, this chapter will discuss and present techniques to work with maturing human basophils.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Lichtenstein LM, Osler AG (1964) Studies on the mechanisms of hypersensitivity phenomena. Ix. Histamine release from human leukocytes by ragweed pollen antigen. J Exp Med 120:507–530
Ishizaka T, De BR, Tomioka H, Lichtenstein LM, Ishizaka K (1972) Identification of basophil granulocytes as a site of allergic histamine release. J Immunol 108:1000–1008
Parwaresch MR (1976) The human blood basophil. Springer-Verlag, New York
Arndt D, Parwaresch MR (1977) Kinetics of human basophilic granulocytes. Folia Haematol Int Mag Klin Morphol Blutforsch 104:24–36
Zaidi AK, MacGlashan DW (2010) Regulation of Fc epsilon RI expression during murine basophil maturation: the interplay between IgE, cell division, and Fc epsilon RI synthetic rate. J Immunol 184:1463–1474
Sun LK, Liou NC, Sun NC, Gossett LA, Sun C, Davis FM, MacGlashan DW Jr, Chang TW (1991) Transfectomas expressing both secreted and membrane-bound forms of chimeric IgE with anti-viral specificity. J Immunol 146:199–205
Stallman PJ, Aalberse RC (1977) Quantitation of basophil-bound IgE in atopic and nonatopic subjects. Int Arch Allergy Appl Immunol 54:114–120
Hsu C, MacGlashan J, D.W. (1996) IgE antibody up-regulates high affinity IgE binding on murine bone marrow derived mast cells. Immunol Lett 52:129–134
MacGlashan DW Jr, Bochner BS, Adelman DC, Jardieu PM, Togias A, McKenzie-White J, Sterbinsky SA, Hamilton RG, Lichtenstein LM (1997) Down-regulation of FceRI expression on human basophils during in vivo treatment of atopic patients with anti-IgE antibody. J Immunol 158:1438–1445
Lantz CS, Yamaguchi M, Oettgen HC, Katona IM, Miyajama I, Kinet JP, Galli SJ (1997) IgE regulates mouse basophil FceRI expression in vivo. J Immunol 158:2517–2521
MacGlashan DW Jr, Xia HZ, Schwartz LB, Gong JP (2001) IgE-regulated expression of FceRI in human basophils: control by regulated loss rather than regulated synthesis. J Leuk Biol 70:207–218
Gomez G, Jogie-Brahim S, Shima M, Schwartz LB (2007) Omalizumab reverses the phenotypic and functional effects of IgE-enhanced fc epsilonRI on human skin mast cells. J Immunol 179:1353–1361
MacGlashan D (2004) Loss of receptors and IgE in vivo during treatment with anti-IgE antibody. J Allergy Clin Immunol 114:1472–1474
Beck LA, Marcotte GV, MacGlashan D, Togias A, Saini S (2004) Omalizumab-induced reductions in mast cell Fce psilon RI expression and function. J Allergy Clin Immunol 114:527–530
Denburg JA, Richardson M, Telizyn S, Bienenstock J (1983) Basophil/mast cell precursors in human peripheral blood. Blood 61:775–780
Denburg JA, Messner H, Lim B, Jamal N, Telizyn S, Bienenstock J (1985) Clonal origin of human basophil/mast cells from circulating multipotent hemopoietic progenitors. Exp Hematol 13:185–188
Denburg JA, Telizyn S, Belda A, Dolovich J, Bienenstock J (1985) Increased numbers of circulating basophil progenitors in atopic patients. J Allergy Clin Immunol 76:466–472
Otsuka H, Dolovich J, Befus AD, Telizyn S, Bienenstock J, Denburg JA (1986) Basophilic cell progenitors, nasal metachromatic cells, and peripheral blood basophils in ragweed-allergic patients. J Allergy Clin Immunol 78:365–371
Wood LJ, Sehmi R, Gauvreau GM, Watson RM, Foley R, Denburg JA, O'Byrne PM (1999) An inhaled corticosteroid, budesonide, reduces baseline but not allergen-induced increases in bone marrow inflammatory cell progenitors in asthmatic subjects. Am J Respir Crit Care Med 159:1457–1463
Schweitzer-Stenner R, Pecht I (2005) Death of a dogma or enforcing the artificial: monomeric IgE binding may initiate mast cell response by inducing its receptor aggregation. J Immunol 174:4461–4464
MacGlashan D Jr (2017) FceRI density and spontaneous secretion from human basophils. PLoS One 12:e0179734
Zaidi AK, Saini SS, Macglashan DW Jr (2010) Regulation of Syk kinase and FcRbeta expression in human basophils during treatment with omalizumab. J Allergy Clin Immunol 125(902–908):e7
MacGlashan DW Jr, Savage JH, Wood RA, Saini SS (2012) Suppression of the basophil response to allergen during treatment with omalizumab is dependent on 2 competing factors. J Allergy Clin Immunol 130(1130–1135):e5
Macglashan DW Jr, Saini SS (2013) Omalizumab increases the intrinsic sensitivity of human basophils to IgE-mediated stimulation. J Allergy Clin Immunol 132(906-11):e1–e4
MacGlashan DW Jr (2007) Relationship between Syk and SHIP expression and secretion from human basophils in the general population. J Allergy Clin Immunol 119:626–633
Nag A, Faeder JR, Goldstein B (2010) Shaping the response: the role of FcepsilonRI and Syk expression levels in mast cell signaling. IET Syst Biol 4:334–347
Havard S, Scola AM, Kay LJ, Ishmael SS, Macglashan DW Jr, Peachell PT (2011) Characterization of syk expression in human lung mast cells: relationship with function. Clin Exp Allergy 41:378–388
Ishmael SS, MacGlashan DW Jr (2010) Syk expression in peripheral blood leukocytes, CD34+ progenitors, and CD34-derived basophils. J Leukoc Biol 87:291–300
Arock M, Schneider E, Boissan M, Tricottet V, Dy M (2002) Differentiation of human basophils: an overview of recent advances and pending questions. J Leukoc Biol 71:557–564
Kepley CL, Pfeiffer JR, Schwartz LB, Wilson BS, Oliver JM (1998) The identification and characterization of umbilical cord blood-derived human basophils. J Leukoc Biol 64:474–483
Langdon JM, Schroeder JT, Vonakis BM, Bieneman AP, Chichester K, Macdonald SM (2008) Histamine-releasing factor/translationally controlled tumor protein (HRF/TCTP)-induced histamine release is enhanced with SHIP-1 knockdown in cultured human mast cell and basophil models. J Leukoc Biol 84:1151–1158
Gilbert HS, Ornstein L (1975) Basophil counting with a new staining method using alcian blue. Blood 46:279–286
Peng X, Zhao M, Gao L, Sen R, MacGlashan J, D.W. (2020) Identifying regulatory pathways of SYK expression in human basophils. J Allergy Clin Immunol 145(3):947–957
Eggel A, Baravalle G, Hobi G, Kim B, Buschor P, Forrer P, Shin JS, Vogel M, Stadler BM, Dahinden CA, Jardetzky TS (2014) Accelerated dissociation of IgE-FcepsilonRI complexes by disruptive inhibitors actively desensitizes allergic effector cells. J Allergy Clin Immunol 133(1709-19):e8
MacGlashan D Jr (2015) Facilitated dissociation of IgE versus cell replacement. J Allergy Clin Immunol 135:294–295
Arm JP, Bottoli I, Skerjanec A, Floch D, Groenewegen A, Maahs S, Owen CE, Jones I, Lowe PJ (2014) Pharmacokinetics, pharmacodynamics and safety of QGE031 (ligelizumab), a novel high-affinity anti-IgE antibody, in atopic subjects. Clin Exp Allergy 44:1371–1385
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2020 Springer Science+Business Media, LLC, part of Springer Nature
About this protocol
Cite this protocol
MacGlashan, D. (2020). Modulating the Human Basophil Phenotype During Its Development and Maturation: Basophils Derived from In Vitro Cultures of CD34+ Progenitor Cells. In: Gibbs, B.F., Falcone, F.H. (eds) Basophils and Mast Cells. Methods in Molecular Biology, vol 2163. Humana, New York, NY. https://doi.org/10.1007/978-1-0716-0696-4_6
Download citation
DOI: https://doi.org/10.1007/978-1-0716-0696-4_6
Published:
Publisher Name: Humana, New York, NY
Print ISBN: 978-1-0716-0695-7
Online ISBN: 978-1-0716-0696-4
eBook Packages: Springer Protocols